The Instant Efficacy and Safety of Alverine in Decreasing Portal Hypertension: an Exploratory Pilot Study
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The main purpose of this exploratory study was to investigate the instant efficacy and safety
of alverine oral administration in decreasing portal hypertension.
Condition of disease: Cirrhotic portal hypertension
Intervention/treatment:
Drug: Alverine 60 mg (1 capsule), orally Drug: Alverine 120 mg (2 capsules), orally